Luye Pharma Group Ltd.
LYPHF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.08B
Close$
$0.51
90.3% upside
Current Fair Value
90.3% upsideUndervalued by 90.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.08 Billion |
|---|---|
| Enterprise Value | $5.44 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.15 |
| Beta | 0.87 |
| Outstanding Shares | 3,994,515,953 |
Return
| Return on Equity | 6.95% |
|---|---|
| Return on Assets | 3.11% |
| Return on Invested Capital | 12.42% |
Valuation & Multiples
| P/E Ratio | 8.48 |
|---|---|
| PEG | 36.7 |
| Price to Sales | 0.09 |
| Price to Book Ratio | 0.07 |
| Enterprise Value to Revenue | 0.45 |
| Enterprise Value to EBIT | 1.97 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 2.31 |
| Debt to Equity | 0.81 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 30, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$465.33 M
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$474.45 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Luye Pharma Group Ltd.
5,221 employees
CEO: Dian Bo Liu Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology...